Meanwhile, our data on rolipram-sensitive SCC clearly show a lower activity of PDE isozymes in biopsies from CRN patients (Fig
Meanwhile, our data on rolipram-sensitive SCC clearly show a lower activity of PDE isozymes in biopsies from CRN patients (Fig. 2), while data on PDE4B from neighboring tissues in the same CRN patients point to both an increased expression (Fig. 4), and an augmented abundance of protein (Fig. 5). of PDE3A (p= 0. 04) and a higher amount of PDE4B (p= 0. 02) in samples from colorectal neoplasia patients. == Conclusion == In conclusion, functional data indicated lower activity of PDE4 subtypes while expressional and abundance data indicated a higher expression of PDE4B in patients with colorectal neoplasia. We suggest that cyclic nucleotide-PDE4B is overexpressed as a malfunctioning protein in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia. If a predisposition of reduced PDE4B activity in colonic mucosa from colorectal neoplasia patients is substantiated further, this subtype could be a potential novel early diagnostic risk marker and may even be a Doxorubicin target for future medical preventive treatment of Doxorubicin colorectal cancer. == Electronic supplementary material == The online version of this article (doi: 10. 1186/s12885-016-2980-z) contains supplementary material, which is available to authorized users. Keywords: Endoscopic biopsy, Human, Cyclic nucleotide phosphodiesterases and colorectal cancer == Background == Colorectal cancer (CRC) is a major Doxorubicin global health problem and has one of the lowest survival rates for all types of cancers [1]. Colorectal neoplasia (CRN) is correlated with the development of CRC [2]. The pathogenesis and etiology of CRC and CRN are still not fully understood. With regards to CRC, non-steroidal anti-inflammatory drugs (NSAIDs) decrease mortality rate and inhibitde novodisease development. The exact mechanism by which NSAIDs exert their anticarcinogenic effect is not completely understood [3, 4]. Investigators attribute part of the Hapln1 anticancer activity of NSAIDs to their inhibition of the cyclooxygenase (COX) enzymes, leading to a decrease in activity of prostaglandins and cyclic adenosine monophosphate (cAMP) [5, 6]. Recently some COX-independent targets have been identified as Doxorubicin being involved in the anticancer effects of NSAIDs [3, 710]. Moreover, both cAMP and cyclic guanosine monophosphate (cGMP) phosphodiesterases (PDEs) have gained particular interest in relation to CRN [3, 11, 12]. PDEs are metallophoshydrolases which specifically hydrolyzes the 3, 5-cyclic phosphate moiety in cyclic nucleotides (cNTs) to a non-cyclic 5 monophosphate, thereby deactivating cAMP and cGMP. PDE activity terminates second messenger signaling by degrading cNTs, whereas inhibition of PDE activity blocks cNT hydrolysis to mimic or amplify cNT signaling. The PDE superfamily consists of 20 distinct genes divided into 11 protein families, PDE1-11 [13]. Studies on human colon cancer cell lines show decreased levels of cGMP and elevated levels of PDE5 mRNA [3, 14], indicating a perturbed activity of the PDEs involved in degrading cGMP in CRC. Similar studies have been conducted investigating the role of cAMP in CRC [4]. However , studies in cancer cell lines, show conflicting outcomes regarding the role of prostaglandins, cAMP and cGMP in CRN and CRC pathogenesis [1520]. In order to identify a potential predisposition in colonic mucosa for development of CRN in non-neoplastic colon, we decided to study the function, expression and localization of several PDE subtypes in specimens of endoscopically non-neoplastic appearing colonic mucosa. == Methods == == Aim == The aim of this study was to investigate function, expression and localization/abundance of selected PDEs in biopsies from non-neoplastic appearing colonic mucosa obtained from patients with and without CRN. Thus, questioning if a possible predisposition to the cancer disease exists in non-neoplastic appearing colonic mucosa. == Study population == Patients Doxorubicin referred for a colonoscopy on suspicion of CRC, were included and divided into two groups. The first group consisted of patients with present or history of CRN, while the second group was control patients (i. e. CTRL) with no present or history of CRN. Patients with incomplete colonoscopy, hemorrhagic diathesis, and inflammatory bowel disease or with previous sigmoid resection were excluded from the study. A total of 27 subjects were enrolled, hereof 12 CRN-subjects (4 women) and 15 CTRLs (7 women). For each patient, we noted age, body mass index (BMI), previous illnesses, medication , all signs of earlier colorectal disease and the findings during the colonoscopy. Age and BMI were well balanced between groups. Mean age (SEM) for CTRL patients was 58 3. 7 and for CRN patients 66 3. 7 years. Mean BMI was 24. 9 1 . 5 in CTRL patients and 26. 2 0. 9 in CRN patients. Eight patients from the CTRL and 6 patients from the CRN group had comorbidities such as ischemic heart disease, heart failure, hypertension, atrial fibrillation, diabetes, kidney failure, chronic obstructive lung disease, dyslipidemia, intermittent claudication, peptic ulcer.